

ACCRELIST LTD. (亚联盛控股公司)

(Company Registration No. 198600445D)
(Incorporated in the Republic of Singapore)

PROPOSED INCREASE IN SHARE CAPITAL OF INDIRECT SUBSIDIARY

The board of Directors (the “**Board**”) of Accrelist Ltd (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) wishes to announce that the share capital of 娅美联晟医美管理 (海南) 有限公司 (Accrelist Medical Aesthetics (Hainan) Pte. Ltd.) (the “**Chinese Subsidiary**”) will be increased from RMB 1,000,000 to RMB 10,000,000 by way of allotment and issuance of new shares capitalising the internal funding from Accrelist Medical Aesthetic (BM) Pte Ltd (“**BM**”), a wholly-owned subsidiary of the Company, and is not subject to the completion of the BM Restructuring as defined in the Company’s separate announcement titled “*Proposed Internal Restructuring of Subsidiaries Within The Group’s Medical Aesthetic Business*” released on the SGXNet today.

The Chinese Subsidiary is a company incorporated in the People’s Republic of China, and BM holds 95% of the Chinese’s Subsidiary’s total issued share capital, or approximately 950,000 shares as at the date of this announcement. Upon the increase in the share capital in the Chinese Subsidiary, BM’s shareholding in the Chinese Subsidiary will increase to 9,500,000 and the unrelated third-party’s shareholding will increase to 500,000, with their respective holdings of 95% and 5% remaining unchanged.

The increase in the Chinese Subsidiary’s share capital is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 March 2024.

None of the directors or controlling shareholders of the Company has any interest, direct or indirect, in the increase of share capital of the Chinese Subsidiary, other than through their respective shareholding interest, direct or indirect, in the Company.

The Company shall update the Shareholders of any material developments related to the increase in share capital of the Chinese Subsidiary.

BY ORDER OF THE BOARD

Dr. Terence Tea
Executive Chairman & Managing Director
3 April 2024

This announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, RHT Capital Pte. Ltd. (“Sponsor”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (“SGX-ST”).

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Joseph Au, Registered Professional, RHT Capital Pte. Ltd., 36 Robinson Road, #10-06 City House, Singapore 068877, sponsor@rhtgoc.com.